CAJ | 학술논문

目的：评价鼠神经生长因子联合α-硫辛酸治疗糖尿病周围神经病变的疗效及安全性。方法糖尿病周围神经病变患者随机分为2组，对照组43例和治疗组45例，均常规给予糖尿病饮食，用胰岛素或口服降糖药控制血糖，对照组静脉滴注α-硫辛酸注射液0．6 g，qd；治疗组在对照组基础上肌内注射鼠神经生长因子注射液20μg，qd，疗程均为21 d。2组均在治疗前后分别记录总症状评分（TSS）、神经传导速度，并测定尿微量白蛋白、超敏 C 反应蛋白水平。结果治疗后，2组神经传导速度较治疗前均显著提高，TSS 评分改善（P ＜0．01）；治疗组尿微量白蛋白、C 反应蛋白水平较对照组均显著下降（P ＜0．05）。治疗组总有效率和神经传导速度显著高于对照组（P ＜0．05）。结论鼠神经生长因子联合α-硫辛酸治疗糖尿病周围神经病变安全有效。
목적：평개서신경생장인자연합α-류신산치료당뇨병주위신경병변적료효급안전성。방법당뇨병주위신경병변환자수궤분위2조，대조조43례화치료조45례，균상규급여당뇨병음식，용이도소혹구복강당약공제혈당，대조조정맥적주α-류신산주사액0．6 g，qd；치료조재대조조기출상기내주사서신경생장인자주사액20μg，qd，료정균위21 d。2조균재치료전후분별기록총증상평분（TSS）、신경전도속도，병측정뇨미량백단백、초민 C 반응단백수평。결과치료후，2조신경전도속도교치료전균현저제고，TSS 평분개선（P ＜0．01）；치료조뇨미량백단백、C 반응단백수평교대조조균현저하강（P ＜0．05）。치료조총유효솔화신경전도속도현저고우대조조（P ＜0．05）。결론서신경생장인자연합α-류신산치료당뇨병주위신경병변안전유효。
Objective To observe the efficacy and safety of the rat nerve growth factor combined with αlipoic acid in the treatment of diabetic periph-eral neuropathy (DPN).Methods Eighty -eight patients with DPN were randomly divided into two groups and they were given diabetes diet and insu -lin or oral hypoglycemic agents to control blood sugar.The control group (n =43) was given αlipoic acid 0.6 g,qd; the trial group (n =45) were given rat nerve growth factor injection 20 μg based on the control group,im, qd.Twenty -one days as a treatment cycle.Before and after treatment, the total symptom score(TSS) ,the nerve conduction velocity(NCV),microalbu-minuria and high sensitivity C -reactive protein were tested and recorded respectively before and after treatment in 2 groups.Results The NCV of the trial group was higher than those of the control group (P <0.01); after treatment,TSS was significantly lower in the trial group than in the control group (P <0.01); the microalbuminuria and high sensitivity C -reactive protein of the trial group descended more apparently than those of the control group (P <0.05).The total effective rate of the trial group was higher than that of the control group (P <0.05).Conclusion Rat nerve growth factor combined with αlipoic acid treatment is safe and effective for the treatment of diabetic peripheral neuropathy.